Avalo Had $59,000 in Revenue. Then It Raised $375 Million Anyway.

Avalo Therapeutics had $59,000 in product revenue last year. That is not a typo.

The struggling biotech, which has no drug on the market and has watched its revenue collapse 87 percent from $441,000 in 2024 according to its SEC filings, announced a Phase 2 win for its anti-IL-1β antibody abdakibart on Monday. By Thursday, it had priced a $375 million public offering.

The market called it a comeback. The numbers tell a different story.

Avalo's pre-offering market cap sat at roughly $368 million on May 4, according to market data. The $375 million the company raised is nearly equivalent to its entire market value before the announcement. The company issued 19.73 million new shares at $17.75 per share, plus 1.4 million pre-funded warrants, per the offering pricing announcement. The math is straightforward: if Avalo had roughly 20.7 million shares outstanding before the offering, the new issuance nearly doubles the share count. Existing shareholders who do not participate see their stake cut roughly in half. That is not a turnaround. It is a refinancing of a science bet, executed at the only moment the company had leverage to do it.

The Phase 2 data itself is real. In the LOTUS trial of 253 adults with moderate-to-severe hidradenitis suppurativa, abdakibart hit its primary endpoint at both dose levels. At 150mg, 42.2 percent of patients achieved HiSCR75, a 75 percent reduction in inflammatory nodules and abscesses, versus 25.6 percent on placebo. At 300mg, 42.9 percent hit the same threshold. Both results were statistically significant.

CEO Garry Neil has argued that a pure anti-IL-1β approach could offer advantages over AbbVie's bispecific lutikizumab, which targets both IL-1α and IL-1β. Neil made that case publicly at a March 2026 conference, before the data was in. Sixteen weeks later, he has a Phase 2 result to point to. Whether the mechanistic bet pays off in Phase 3 remains an open question.

The competitive landscape adds pressure. Three biologic medications are currently approved for moderate-to-severe HS: adalimumab (Humira, anti-TNFα, approved in 2015), secukinumab (Cosentyx, anti-IL-17A, approved in 2023), and bimekizumab (Bimzelx, anti-IL-17 A/F, approved in November 2024). AbbVie's lutikizumab is already in Phase 3. If abdakibart succeeds, it enters a market with entrenched competitors and no head-to-head data. If it fails, Avalo has no second asset in queue — the company's pipeline beyond abdakibart is not disclosed as a near-term replacement.

Phase 3 for an immunology biologic typically runs $200 million to $500 million, according to industry cost benchmarks. The $375 million Avalo just raised buys roughly one Phase 3 trial, assuming typical costs. If the trial succeeds, approval follows. If it does not, the company returns to the financing table with the same near-zero revenue problem it has today.

Avalo's cash position was $98.3 million as of December 31, 2025, according to its annual report filed with the SEC. The company had been burning roughly $20-30 million per quarter, according to its periodic filings, which explains why a company with $59,000 in annual revenue was burning cash at that rate — the science was keeping it alive, not the business. The Phase 2 result gave Avalo's bankers the cover to go back to investors and ask for enough money to run a registrational trial. The timing was opportunistic. It was not a celebration.

For investors who held through the lean years, the dilution is real and immediate. At the new share count, their stake is worth roughly half what it was before the offering, on a per-share basis, assuming the stock does not move. Insiders who participated in prior rounds likely bought the new shares to protect their positions — that is standard practice and not evidence of confidence. It is evidence of alignment.

The HS market is real and underserved. Hidradenitis suppurativa is a chronic, progressive, inflammatory skin disease affecting roughly 1 percent of the US population, with onset typically in late adolescence or early adulthood. The physical and emotional burden is significant. AbbVie's Humira once dominated the space, and the post-Biosimilar landscape has created genuine room for newcomers with better profiles. If abdakibart can show durable response and a clean safety profile in Phase 3, there is a commercial opportunity.

That is a large "if." Phase 2 hits matter, but they do not predict Phase 3. The LOTUS trial enrolled 253 patients over 16 weeks. Registrational trials for HS have required thousands of patients and years of follow-up. The placebo rate of 25.6 percent, while within range for this population, raises questions about which patients benefit and whether the effect holds across disease subtypes and prior biologic exposure history. Long-term durability, immunogenicity, and safety at the doses needed for efficacy remain open questions.

Avalo is not a turnaround story. It is a refinancing of a science bet, executed at a moment when the science briefly cooperated. The $375 million buys time. What happens next depends entirely on whether the Phase 2 signal survives contact with the harder questions Phase 3 is designed to ask.